Replies to post #3392 on BANKRUPTCY PLAYS (CHAPTER)

[I Like Bottom Fishing]

I am not sure what the hell is going on here but that sob MM nite has been messing with my head this dam stock should have pop a week ago imo! wee will see tomorrow i hope we got his ass cornered no wonder he was trying to take the osciq chart play down to 0.04, I think we are ready to go now these dam MM got me so confuse on this one, I don't know what the hell is going on! But here is the news dd research i did on osciq!

This Lupin Bio Company is out of India.

Thomson Reuters Lupin buys cholesterol-lowering drug for $38.61 mln

Tue Sep 29, 2009 10:06am IST

http://in.reuters.com/article/companyNews/idINBOM48848320090929

MUMBAI, Sept 29 (Reuters) - Drug maker Lupin Ltd (LUPN.BO: Quote, Profile, Research) said on Tuesday it bought U.S. rights for Antara, a cholesterol-lowering drug, for $38.61 million from U.S.-listed Oscient Pharamaceuticals OSCI.O.

The deal for Antara, or Fenofibrate capsules of 43 mg and 130 mg dosages, include product related assets and inclusive inventory, and was struck under US bankruptcy procedures, Lupin said in a statement.

The buy will help contribute to the revenue as well as profit, Vinita Gupta, group president and chief executive, Lupin, said in the statement.

The drug recorded a net sales of $70 million for 2008, the company said.

Earlier, Lupin had filed an ANDA for Fenofibrate capsules, but sold it to Dr. Reddy's Laboratories (REDY.BO: Quote, Profile, Research) prior to buying product rights from Oscient, the company added.

In July, US listed Oscient had filed for chapter 11 bankruptcy protection in the US court and sold its antibiotic drug Factive to a unit of Cornerstone Therapeutics Inc (CRTX.O: Quote, Profile, Research) for $5 million.

(Reporting by Ketan Bondre; Editing by Ramya Venugopal)

http://in.reuters.com/article/companyNews/idINBOM48848320090929

© Thomson Reuters 2009 All rights reserved


News for OSCIQ News Lupin Expands Branded Play --Announces Acquisition

Tuesday, September 29, 2009 4:45 PM

Scottrade.com
This email is compliments of Scottrade.com

News for 'OSCIQ' - (Lupin Expands Branded Play --Announces Acquisition of US Rights to ANTARA)

MUMBAI, India, Sept 29, 2009 /PRNewswire-FirstCall via COMTEX/ --
Pharmaceutical Major, Lupin Ltd. announced today the acquisition of US rights
for Antara(R) (Fenofibrate Capsules 43 mg and 130 mg). Lupin acquired the
product from Oscient Pharmaceuticals on September 25, 2009, under the procedures
of the U.S. Bankruptcy Court. Antara recorded net sales of US $ 70 million for
2008 (Source: IMS Dec 2008). Lupin paid $ 38.61 million for the product and
related assets inclusive of inventory.

Lupin had previously filed an ANDA for Fenofibrate Capsules 43 mg and 130 mg. On
September 21, 2009, prior to the acquisition of Antara(R), Lupin sold its ANDA
to Dr. Reddy's Laboratories. Lupin also settled and resolved the pending
litigation regarding the ANDA product.

Prior to the acquisition, Antara(R) was marketed by Oscient Pharmaceuticals.
Antara(R) has a strong brand equity with primary care physicians treating
patients for high LDL-C, Total-C, triglycerides, Apo-B and low HDL-C. The
Fenofibrate products market is $ 1.9 Billion for the last 12 months. Antara(R)
has 4.5% share of this market and grew 20 % in revenue this past year. Antara(R)
is prescribed for adjunct treatment of hypercholesterolemia (high blood
cholesterol) and hyper-triglyceridemia (high triglycerides) in combination with
diet.

The Antara acquisition enables Lupin to enter the primary care market with a
three product portfolio. Lupin's Suprax Tabs and Allernaze have strong potential
in primary care. Lupin will be more than doubling its sales force size in the
next 12 months to reach the key targets for the three products.

"We are very excited with our 2nd NDA acquisition within a span of 4 months. The
Antara(R) acquisition demonstrates Lupin's success in, and commitment to
building its brand franchise and equity in the US. It underlines Lupin's
differentiated strategy for the US market. Antara(R) is a step forward that will
help us strengthen and grow our brand business. Since Antara(R) is a previously
approved, commercial product, our sales and marketing efforts will commence
immediately and we are optimistic of it contributing positively to our topline
and bottomline in the coming quarters and years," said Vinita Gupta, Group
President & CEO, Lupin Pharmaceuticals Inc

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational
pharmaceutical company producing a wide range of quality, affordable generic and
branded formulations and APIs for the developed and developing markets of the
world. The Company today has significant market share in key markets in the
Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI,
Anti-Infectives and NSAIDs therapy segments, not to mention global leadership
positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have
resulted in significant progress in its NCE program. The Company's foray into
Advanced Drug Delivery Systems has resulted in the development of platform
technologies that are being used to develop value-added generic pharmaceuticals.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has
the unique distinction of being the fastest growing top 10 Generics player in
the two largest pharmaceutical markets of the world -- The U.S. (ranked 9th by
prescriptions & growing at 92 %) and Japan (ranked 7th and growing at 23%). The
company is also the fastest growing, top 5 pharmaceutical player in India (ORG
IMS - March 2009) and the fastest growing Generic player in South Africa (ranked
6th and growing at over 30 % YoY - IMS)

For the financial year ended March 2009, Lupin's Consolidated Revenues and
Profit after Tax were Rs. 39,145 million and Rs. 5015 million respectively.

BSE: 500257 NSE: Lupin REUTERS: LUPN.BO BLOOMBERG: LPC IN

For further information contact:

Shamsher Gorawara

Head - Corporate Communications

Lupin Limited

[e-mail]

Mobile: [phone]

OR

Sonia Mansata

Text 100

[e-mail]

Mobile: [phone]

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act
of 1995:

This release contains forward-looking statements that involve known and unknown
risks, uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Many of these risks, uncertainties and
other factors include failure of clinical trials, delays in development,
registration and product approvals, changes in the competitive environment,
increased government control over pricing, fluctuations in the capital and
foreign exchange markets and the ability to maintain patent and other
intellectual property protection. The information presented in this release
represents management's expectations and intentions as of this date. Lupin
expressly disavows any obligation to update the information presented in this
release.

SOURCE Lupin Limited

www.prnewswire.com

Copyright (C) 2009 PR Newswire. All rights reserved

-0-

KEYWORD: India

INDUSTRY KEYWORD: PHA

MTC

HEA

SUBJECT CODE: TNM

Source: Comtext Market News

[I Like Bottom Fishing]

Oscient Pharmaceuticals Corporation (pinksheets:OSCIQ) Stock Symbol:Company Profile:
http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ
Knobias MEMBERS get: Quotes | Charts | Technical Analysis | Quick Profiles | EDGAR Filings | News & Alerts | TearSheet Profiles | Historical Statistics | Insider Transactions | Institutional Holdings | ...and Much More
http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

Last Trade: 0.056 Change: -0.003 ( -4.310 %)
Previous Close: 0.058 Today's Open: 0.060
# of Trades: 39 Volume: 427,353
Avg. # of Trades: 55 Avg. Daily Volume: 1,032,610

Bid: N/A Bid Size: N/A
Ask: N/A Ask Size: N/A
Day High: 0.060 Day Low: 0.055
52 Week High: 1.170 52 Week Low: 0.016
Market Cap: 2.16M Dividend: N/A
EPS: N/A P/E Ratio: N/A

6 Month Chart

RAiDAR alerts Learn More About RAiDAR-LT
09/29/2009 (22:58 ET) INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN - AsiaPulse Pte. Ltd
09/09/2009 (07:10 ET) Cornerstone Wins Factive Rights - Zacks.com
09/05/2009 (13:07 ET) Cornerstone wins approval to acquire rights to Oscient's antibiotic drug - Datamonitor
09/03/2009 (08:01 ET) Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R) - PR Newswire
08/10/2009 (09:50 ET) OSCIQ: New 52-Wk Low @ $0.020 dn 20% - Knobias
08/07/2009 (12:40 ET) OSCIQ: New 52-Wk Low @ $0.025 dn 9.26% - Knobias
08/06/2009 (15:10 ET) OSCIQ: New 52-Wk Low @ $0.026 dn 13.33% - Knobias
07/31/2009 (12:00 ET) OSCIQ: New 52-Wk Low @ $0.028 dn 12.5% - Knobias
07/30/2009 (10:10 ET) OSCIQ: New 52-Wk Low @ $0.029 dn 6.35% - Knobias
07/28/2009 (09:55 ET) OSCIQ: Filed New Form 25-NSE - Edgar
07/22/2009 (03:12 ET) The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health - PRWeb.com
07/20/2009 (11:40 ET) OSCI: Volume Spike; 43% > 20-adsv, Stock +53.25% - Knobias
07/20/2009 (10:10 ET) OSCI: New 52-Wk Low @ $0.035 dn 9.09% - Knobias
07/17/2009 (12:10 ET) OSCI: New 52-Wk Low @ $0.041 dn 16.12% - Knobias
07/17/2009 (08:20 ET) AnalystChoice.com Brings You the Best Complimentary Research Report on DLTR, PMCS, CMCSA, DDUP, CREE and OSCI - Market Wire
07/15/2009 (08:51 ET) Oscient Pharmaceuticals files for Chapter 11 bankruptcy protection - Datamonitor
07/15/2009 (07:10 ET) Cornerstone Buys OSCI Antibiotic - Zacks.com
07/14/2009 (23:07 ET) Oscient Pharmaceuticals Files for Chapter 11 Relief - Close-Up Media
07/14/2009 (13:16 ET) Cornerstone Therapeutics signs asset purchase agreement with Oscient - Datamonitor
07/14/2009 (07:40 ET) Cornerstone Therapeutics To Buy Factive Rights - Investrend
07/13/2009 (17:51 ET) OSCI: Files Chapter 11; To Sale Assets of FACTIVE to Cornerstone Therapeutics - Knobias
07/13/2009 (17:35 ET) Cornerstone Therapeutics Signs Definitive Asset Purchase Agreement to Acquire Commercial Rights to the Antibiotic Factive(R) - PR Newswire
07/13/2009 (17:12 ET) OSCI: Filed New Form 8-K, Material Event Disclosure - Edgar
07/13/2009 (17:05 ET) Oscient Pharmaceuticals Files Voluntary Petition for Relief Under Chapter 11 of the United States Bankruptcy Code - Business Wire

company profile
A commercial-stage pharmaceutical company, which markets products to primary care physicians, cardiologists, endocrinologists and pulmonologists in the United States. ... MORE INFO

CONTACT: Steven M. Rauscher (CEO)
Oscient Pharmaceuticals Corporation
1000 Winter Street
Suite 2200
Waltham, MA 02451
P: [phone]
P: [phone] / [phone]
F: [phone]
Company Home Page | Email

Industry: Drugs
SIC: 2834
Employees: 316
Locations: 0

State of Inc: MASSACHUSETTS
Development Stage? N Transfer Agent:
Computershare Investor Services
Golden, CO 80401

Investor Relations:
Company Authorized Shares: 174,375,000
Source: 10-Q ( 09/30/2006 )

Outstanding Shares: 39,003,978
Source: MGFS ( 03/20/2009 )

Fiscal Year End: December 31

MANAGEMENT & INSIDERS:

Need More Stock Research? Subscribe NOW!!!

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN

Tuesday , September 29, 2009 22:58ET

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

MUMBAI, Sep 30, 2009 (AsiaPulse via COMTEX) -- India's Lupin Pharmaceuticals (BSE:500257)has bought the US marketing rights of cholestrol-lowering drug Antara and related assets from bankrupt American entity Oscient Pharmaceuticals for US$38.61 million.

In a filing to the Bombay Stock Exchange, Lupin said it paid US$38.61 million for the product and related assets, inclusive of inventory.

The firm has acquired the US rights for Antara (Fenofibrate capsules in the strength of 43 mg and 130 mg) on September 25, under the procedure of US bankruptcy court.

Earlier, Lupin had filed an Abbreviated New Drug Application (ANDA) for Fenofibrate capsules of the same composition.

"On September 21, 2009, prior to the acquisition of Antara, Lupin sold its ANDA to Dr Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product," the filing said.

Acquisition of Anatara would enable Lupin to enter the primary care market with a three-product portfolio. The two other products are Suprax, used for treating bacterial infections, and Allernaze, prescribed for various allergies.

The filing noted that the firm would be more than doubling its sales force size in the next 12 months to reach key targets for these products.

"The Antara acquisition demonstrates Lupin's success in and commitment to building its brand franchise and equity in the US. Antara is a step forward that will help us strengthen and grow our brand business.

"Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our top line and bottom line in the coming quarters and years," Lupin President and CFO Vinita Gupta said.

According to a data from drug sales tracking agency IMS, Antara recorded a net sales of USD 70 million in 2008.

(PTI) cg

(C) 2009 Asia Pulse Pte Ltd


Public Companies Associated with this story:
OSCIQ

Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.


INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN

Tuesday , September 29, 2009 22:58ET

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

MUMBAI, Sep 30, 2009 (AsiaPulse via COMTEX) -- India's Lupin Pharmaceuticals (BSE:500257)has bought the US marketing rights of cholestrol-lowering drug Antara and related assets from bankrupt American entity Oscient Pharmaceuticals for US$38.61 million.

In a filing to the Bombay Stock Exchange, Lupin said it paid US$38.61 million for the product and related assets, inclusive of inventory.

The firm has acquired the US rights for Antara (Fenofibrate capsules in the strength of 43 mg and 130 mg) on September 25, under the procedure of US bankruptcy court.

Earlier, Lupin had filed an Abbreviated New Drug Application (ANDA) for Fenofibrate capsules of the same composition.

"On September 21, 2009, prior to the acquisition of Antara, Lupin sold its ANDA to Dr Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product," the filing said.

Acquisition of Anatara would enable Lupin to enter the primary care market with a three-product portfolio. The two other products are Suprax, used for treating bacterial infections, and Allernaze, prescribed for various allergies.

The filing noted that the firm would be more than doubling its sales force size in the next 12 months to reach key targets for these products.

"The Antara acquisition demonstrates Lupin's success in and commitment to building its brand franchise and equity in the US. Antara is a step forward that will help us strengthen and grow our brand business.

"Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our top line and bottom line in the coming quarters and years," Lupin President and CFO Vinita Gupta said.

According to a data from drug sales tracking agency IMS, Antara recorded a net sales of USD 70 million in 2008.

(PTI) cg

(C) 2009 Asia Pulse Pte Ltd


Public Companies Associated with this story:
OSCIQ

Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

[I Like Bottom Fishing]

INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN

Tuesday , September 29, 2009 22:58ET

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

MUMBAI, Sep 30, 2009 (AsiaPulse via COMTEX) -- India's Lupin Pharmaceuticals (BSE:500257)has bought the US marketing rights of cholestrol-lowering drug Antara and related assets from bankrupt American entity Oscient Pharmaceuticals for US$38.61 million.

In a filing to the Bombay Stock Exchange, Lupin said it paid US$38.61 million for the product and related assets, inclusive of inventory.

The firm has acquired the US rights for Antara (Fenofibrate capsules in the strength of 43 mg and 130 mg) on September 25, under the procedure of US bankruptcy court.

Earlier, Lupin had filed an Abbreviated New Drug Application (ANDA) for Fenofibrate capsules of the same composition.

"On September 21, 2009, prior to the acquisition of Antara, Lupin sold its ANDA to Dr Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product," the filing said.

Acquisition of Anatara would enable Lupin to enter the primary care market with a three-product portfolio. The two other products are Suprax, used for treating bacterial infections, and Allernaze, prescribed for various allergies.

The filing noted that the firm would be more than doubling its sales force size in the next 12 months to reach key targets for these products.

"The Antara acquisition demonstrates Lupin's success in and commitment to building its brand franchise and equity in the US. Antara is a step forward that will help us strengthen and grow our brand business.

"Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our top line and bottom line in the coming quarters and years," Lupin President and CFO Vinita Gupta said.

According to a data from drug sales tracking agency IMS, Antara recorded a net sales of USD 70 million in 2008.

(PTI) cg

(C) 2009 Asia Pulse Pte Ltd


Public Companies Associated with this story:
OSCIQ

Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

[I Like Bottom Fishing]

A photo view of level2 and time and sells for OSCIQ.
OSCIQ is ready to explode, no doubt about it.



OSCIQ: MM's came down and hit the 50 sma at 0.05 and bounce off the 50 sma.

[I Like Bottom Fishing]

Hey what about the money from the sale of those two products that they sold through the bankruptcy court what did the court do with that money and how much is going to osciq company bottom line after pay off the bond holders and all the other debt holders that they own money two maybe after the court divide the money up and pay off everyone and then what is left over should take us up from here, now what the hell is the bankruptcy court conservator doing with the money from the product sales, I bet that is what we are waiting on here with OSCIQ???

CTIC v/s OSCIQ Chart Play*
Hey buddy what your take on these two chart plays.







































http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ


OQCIQ short interest data numbers.
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=osciq#getShortInfo

INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN

Tuesday , September 29, 2009 22:58ET

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

MUMBAI, Sep 30, 2009 (AsiaPulse via COMTEX) -- India's Lupin Pharmaceuticals (BSE:500257)has bought the US marketing rights of cholestrol-lowering drug Antara and related assets from bankrupt American entity Oscient Pharmaceuticals for US$38.61 million.

In a filing to the Bombay Stock Exchange, Lupin said it paid US$38.61 million for the product and related assets, inclusive of inventory.

The firm has acquired the US rights for Antara (Fenofibrate capsules in the strength of 43 mg and 130 mg) on September 25, under the procedure of US bankruptcy court.

Earlier, Lupin had filed an Abbreviated New Drug Application (ANDA) for Fenofibrate capsules of the same composition.

"On September 21, 2009, prior to the acquisition of Antara, Lupin sold its ANDA to Dr Reddy's Laboratories. Lupin also settled and resolved the pending litigation regarding the ANDA product," the filing said.

Acquisition of Anatara would enable Lupin to enter the primary care market with a three-product portfolio. The two other products are Suprax, used for treating bacterial infections, and Allernaze, prescribed for various allergies.

The filing noted that the firm would be more than doubling its sales force size in the next 12 months to reach key targets for these products.

"The Antara acquisition demonstrates Lupin's success in and commitment to building its brand franchise and equity in the US. Antara is a step forward that will help us strengthen and grow our brand business.

"Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately and we are optimistic of it contributing positively to our top line and bottom line in the coming quarters and years," Lupin President and CFO Vinita Gupta said.

According to a data from drug sales tracking agency IMS, Antara recorded a net sales of USD 70 million in 2008.

(PTI) cg

(C) 2009 Asia Pulse Pte Ltd


Public Companies Associated with this story:
OSCIQ

Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/story.htm?eid=3.1.6f5a8783c869e0a8f76daebfa9ffe274e339f44675ade9094342554153c0e7e7

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

[I Like Bottom Fishing]

OSCIQ MM Nite level2 and chart play, let the games began I have to be honest I am so confuse here on the Osciq chart play and level2 fighting a in house battle among the bankruptcy court bond holders & credit debtor's and the MM's being keep out of the lop or due they really know what is going on here i am for sure even thosee MM's have there bankruptcy spies eying and monitoring Osciq you think?





The osciq credit debtors and bond holders all want a peace of me osciq court conservator running as bond holders and other unpaid credit holders all want there money so where is all the money that went to osciq bankruptcy court in the recent sell of osciq drug sale to the companies listed below.
09/29/2009 (23:42 ET) India's Lupin buys US rights for cholesterol drug Antara - AsiaPulse Pte. Ltd. - Asia In Focus
09/29/2009 (22:58 ET) INDIA'S LUPIN BUYS US MKT RIGHTS OF ANTARA DRUG FOR US$38.61 MLN - AsiaPulse Pte. Ltd
09/09/2009 (07:10 ET) Cornerstone Wins Factive Rights - Zacks.com
09/05/2009 (13:07 ET) Cornerstone wins approval to acquire rights to Oscient's antibiotic drug - Datamonitor
09/03/2009 (08:01 ET) Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R) - PR Newswire

Qsciq poker game among bankruptcy court bond holders credit holders MM's share holders all bluffing each other who will blink first here in this high steak game of confuse poker players.

Qsciq Political term oil and bankruptcy court conservator & debt creditors in a battle along with confuse greedy Osciq MM's not knowning witch way the wind is going to blow!

There can be only one winner here!

I could not find a osciq nut so i am drinking all of the osciq kool aid!